Introduction {#s02}
============

Pumping by the heart results from the synchronous contraction and relaxation of billions of cardiac cells. Immediately after each heartbeat and during relaxation, the cardiac muscle becomes functionally silent and will not respond to external electrical stimuli for a distinct time period. Although known to Italian physiologists in the 18th century, the discovery of this fundamental property of the heart is commonly attributed to the French cardiologist Eitienne-Jules Marey, who introduced the term "mechanical refractoriness" to describe this phenomenon in 1875 ([@bib38]). We now know that a temporary inactivation of Ca signaling underlies mechanical refractoriness and that it is likely mediated by mechanisms operating within the lumen of the SR. In this perspective, we review experimental and theoretical evidence for the regulation of SR Ca release by luminal Ca and examine how that mechanism contributes to Ca signaling refractoriness. We also discuss how alterations in this mechanism give rise to triggered arrhythmias. In particular, we summarize recent work showing how shortened refractoriness of cardiac ryanodine receptor (*RyR2*) channels results in synchronization of aberrant SR Ca release to cause arrhythmias.

Cardiac refractoriness {#s03}
======================

Mechanical refractory period is defined as the time required for full recovery of cardiac contractile force after contraction. Quantitative assessment of contractile restitution performed beginning from the 1950s in various cardiac muscle preparations demonstrated that, in the mammalian heart, mechanical refractoriness lasts ∼1 s (0.5--2 s, depending on species and experimental conditions; [@bib84]; [@bib47]; [@bib31]; [@bib24]). Interestingly, this period was found to be substantially longer than the time required for the recovery of cardiac electrical excitability that initiates the mechanical activity of the heart (0.1--0.3 s; [@bib83]; [@bib14]; [@bib101]). These early observations have led to a general conclusion that, rather than reflecting changes in electrical excitability, the bulk of mechanical restitution is determined by processes occurring at some later steps in the heartbeat generation, beyond that of electrical excitation. Some have even ascribed that refractoriness to "altered metabolism of activator Ca in the excitation--contraction coupling" ([@bib24]).

Currently, the role of Ca in cardiac excitation--contraction (EC) coupling is well defined. Cardiac contraction results from CICR, whereby a small influx of Ca through the sarcolemma triggers the Ca release channels on the SR membrane, RyR2, allowing a release of Ca from the SR stores much greater than the triggering influx. It is that Ca release from the SR that is able to engage the contractile machinery, thereby precipitating contraction ([@bib12]). In contrast, recycling of Ca back to the SR by the SR Ca--ATPase underlies relaxation. During that relaxation period, the functional activity of RyR2 in healthy cardiomyocytes is quenched to prevent further Ca release during diastole ([@bib107]; [@bib19]). This temporary inactivation of Ca signaling opposes the positive feedback of CICR and facilitates mechanical refractoriness of the heart. Notably, impaired Ca-signaling refractoriness results in aberrant diastolic SR Ca release, a major factor underlying cardiac arrhythmias ([@bib9]; [@bib15]). Although the mechanisms of activation of SR Ca release have been well characterized ([@bib16]; [@bib25]; [@bib39]), the processes underlying functional inactivation of release and factors accounting for impaired refractoriness in cardiac disease remain to be fully elucidated. However, evidence accumulated during the past 10--15 yr suggests that Ca signaling and mechanical refractoriness are likely mediated by mechanisms that reside at the luminal side of the SR (for a review, see [@bib91]; [@bib86]; [@bib75]; see Sobie et al. in this issue).

Control of SR Ca release by luminal Ca {#s04}
======================================

Ca release from the SR is, in principle, a self-contained process; once initiated, it should terminate upon depletion of the Ca store. During normal EC coupling, however, only a fraction of the total stored Ca is released from the SR ([@bib4], [@bib5]; [@bib82]). Furthermore, as demonstrated by studies of both cell-wide and local SR Ca release, after each event of Ca release, RyR2s remain refractory to subsequent activation despite refilling of SR Ca stores ([@bib88]; [@bib77]; [@bib9]). These and similar studies led to the general view that CICR from the SR is modulated by some "restraining" mechanisms. In turn, these factors would help SR Ca release to terminate and facilitate relaxation by preventing RyR2 reopening during diastole. Importantly, such mechanisms would also contribute to the mechanical refractoriness of the heart. In contrast, impairment of these factors may result in aberrant diastolic Ca release that can precipitate cardiac arrhythmias in the diseased heart ([@bib86]; [@bib10]; [@bib75]; [@bib13]).

Based on early experiments by [@bib27] in skinned myocytes, the mechanism responsible for termination of Ca release and Ca-cycling refractoriness was believed to involve inactivation of RyR2 by cytosolic Ca. However, subsequent studies conducted either in isolated cardiomyocytes or single RyR2 channels failed to provide substantial evidence in support of that theory ([@bib61]; [@bib22]; [@bib54]; [@bib30]). Instead, work from several laboratories pointed to a different mechanism, which was most likely occurring at the luminal side of the SR.

The possibility of regulation of SR Ca release by luminal Ca was first suggested by experiments conducted in single RyR2 channels reconstituted in bilayers, which revealed that RyR2 activity is considerably diminished at lowered luminal Ca ([@bib85]; [@bib55]; [@bib33]). However, experimental evidence in support of this mechanism in situ was obtained from cellular studies in which the buffering capacity of the SR was exogenously increased by the introduction of Ca chelators into the SR. That strategy allowed for a slower SR Ca depletion without affecting the regulatory processes at the cytosolic side of the RyR2 channel ([@bib94]). Buffering luminal Ca markedly slowed termination of SR Ca release and its restitution thus supporting the notion that termination of Ca release and its restitution are determined by luminal Ca regulation of RyR2 gating. In particular, it was suggested that termination of Ca release and the subsequent suppression of store availability are attributable to deactivation of RyR2 caused by lowered luminal Ca level after Ca release. Important support for this deactivation mechanism also came from mathematical simulations of Ca release termination in a cardiomyocyte model ([@bib87]). That study concluded that local SR Ca depletion coupled to luminal Ca-dependent changes in RyR2 gating was sufficient to account for termination of SR Ca release and release refractoriness in cardiac cells.

The role of luminal regulation of Ca release was further examined in studies that directly assessed depletion of the Ca signal during both global and local release in cardiomyocytes ([@bib82]). These and subsequent studies with intra-SR Ca indicators demonstrated that SR Ca release leaves a substantial reserve of free Ca within the SR after both global Ca transients and local Ca sparks ([@bib48]; [@bib68]; [@bib7]; [@bib114]). This, therefore, offered support for the notion that, rather than causing termination by depletion, changes in luminal Ca modulate RyR2 gating activity to regulate its release.

Modulation of RyR2 by luminal Ca appears also to be consistent with studies that have examined the dependence of SR Ca release on the SR Ca content. In general, Ca release exhibits a steep, highly nonlinear dependency on the SR Ca content in cardiac myocytes ([@bib5]; [@bib81]; [@bib12]; [@bib26]). This behavior has been commonly attributed to an increased recruitment of neighboring Ca release units via CICR as the SR Ca content increases. In addition, it may also involve direct effects of luminal Ca on the RyR2 channel complex, which encompasses accessory regulatory proteins, such as triadin (TRD), junctin (JNT), and histidine-rich Ca-binding protein (HRC). Importantly, [@bib5] found that SR Ca release becomes nearly extinguished when the SR Ca content is lessened only modestly to 60% of its maximal level. Absence of release is a likely indication that lowered luminal Ca has an inhibitory role during Ca cycling, particularly through deactivation of RyR2s.

Recently, several studies have suggested that local depletion might be more complete than initially thought, based on measurements with SR-entrapped Ca indicators (reviewed by [@bib86]; [@bib89]). Some others have pointed to mechanisms other than luminal regulation of RyR2 through which changes in SR Ca content could influence SR Ca release and its termination (see review in Cannell and Kong in this issue). For instance, [@bib32] found that, in permeabilized myocytes, large cations that reduce RyR2 channel permeability suppress Ca sparks and increase SR Ca load. The investigators concluded that the control of local Ca release by SR load is predominantly governed by the RyR2 current and not by the luminal Ca acting on intra-SR sites. Given the intrinsic propensity of SR Ca release to terminate by exhaustion of the Ca store, along with the technical difficulty of measuring or even controlling luminal Ca in cardiac cells, it is challenging to precisely define the contribution of luminal regulation to SR Ca release termination. Thus, despite substantial evidence in support of luminal Ca regulation of SR Ca release, the precise role of this mechanism in Ca release termination yet to be directly demonstrated.

Luminal Ca regulation and Ca signaling refractoriness {#s05}
=====================================================

Similar to contraction and its refractoriness, Ca release becomes functionally suppressed after each release event. For instance, in mammalian cardiomyocytes, analogous to mechanical restitution, full recovery of the Ca transient amplitude takes ∼1 s (0.8--1.5 s depending on species; [@bib22]; [@bib92]; [@bib9]; [@bib46]; [@bib15]; [Fig. 1](#fig1){ref-type="fig"}). There is a growing consensus that control by luminal Ca has a major role in that process. Based on the notion that during Ca release, lesser levels of luminal Ca deactivate RyR2, restitution of Ca release is expected to exhibit strong dependence on luminal Ca. Indeed, that notion is supported by studies that manipulated the rate of SR Ca reuptake to either slow or accelerate SR Ca refilling. For instance, interventions that delay SR Ca reuptake slow Ca signaling restitution, whereas those that facilitate those processes accelerate restitution ([@bib94]; [@bib92]). Importantly, restitution of SR Ca release is preceded by the recovery of Ca in the SR, thus indicating that restitution does not merely reflect Ca store refilling. As was recently demonstrated by our group by simultaneous monitoring the SR and cytosolic Ca ([@bib9]), the recovery of Ca transient amplitude was significantly delayed relative to the refilling of the SR Ca in canine ventricular myocytes ([Fig. 1 B](#fig1){ref-type="fig"}). A significant lag between SR refilling and Ca release channel availability has also been demonstrated at the subcellular level. For example, [@bib88] demonstrated that the triggering probability for repetitive sparks lags behind spark amplitude recovery. Those authors concluded that, in addition to local SR refilling, as reflected by Ca spark amplitude recovery, the triggering probability depends on recovery of RyR2 from refractoriness.

![**Shortened Ca-signaling refractoriness in cardiac disease.** (A) Schematic illustration of a two-pulse protocol experiment showing the recovery of electrically stimulated Ca release is significantly delayed in relation to the recovery of electrical excitability. (B) Exponential constants (tau) of the recovery of Ca-transient amplitude (\[Ca\]~cyt~), free SR Ca (\[Ca\]~SR~), the amplitude of L-type Ca current (I~Ca~), and peak of voltage-gated Na current (I~Na~), are shown for control and diseased myocytes. Data for \[Ca\]~cyt~ and \[Ca\]~SR~ were obtained from the two-pulse experiments in ventricular myocytes from control and diseased hearts ([@bib8], [@bib9]). Rates of recovery for I~Na~ and I~Na~ were obtained with the [@bib40] model of the canine ventricular myocyte. Note the shortened time delay between the recovery of \[Ca\]~cyt~ and \[Ca\]~SR~ in diseased hearts.](JGP_201711808_Fig1){#fig1}

Further support for the role of luminal regulation in Ca-release refractoriness comes from studies of inherited arrhythmia disorders. For instance, catecholaminergic polymorphic ventricular tachycardia (CPVT), which is caused by aberrant Ca release, has also been associated with shortened refractoriness. This is particularly evident in cardiac calsequestrin (CASQ2)-associated CPVT. CASQ2 is thought to regulate the ability of RyR2 to deactivate at lower luminal Ca levels; hence, mutations in *CASQ2*, which decrease its affinity for the Ry2 complex, or its ablation result in impaired RyR2 deactivation and abbreviated Ca-release refractoriness ([@bib45]; [@bib46]; [@bib15]; discussed further in Modulation of Ca-release refractoriness). Of note, recent studies of CPVT have uncovered novel mutations in the cytoplasmic Ca-binding protein CaM ([@bib110]; [@bib63]; [@bib111]; [@bib90]; [@bib102]). Because CaM is known to inhibit RyR2 at elevated \[Ca\], it is possible that this protein also contributes to Ca-release refractoriness by inhibiting RyR2 after SR Ca release, when Ca at the cytosolic side of the channel is increased. These results, therefore, suggest that Ca-release refractoriness is a complex process that not only depends on luminal factors but also may rely on the cytosolic ones.

Collectively, these studies set the stage for our understanding of mechanisms responsible for quenching CICR in cardiac muscle. However, important questions about the specific role that luminal Ca may have in these mechanisms remain unanswered. Although strong support exists, particularly for the contribution of luminal Ca to Ca-signaling refractoriness, the role of luminal Ca in termination of Ca release remains to be clarified. Addressing the precise mechanisms by which local SR Ca depletion influences termination of SR Ca release will require advancement in luminal Ca--assessment techniques, along with novel, genetic mouse models that target the components of the RyR2 complex.

Modulation of Ca-release refractoriness and store availability {#s06}
==============================================================

As an important factor in governing Ca cycling, Ca release refractoriness is subject to physiologic regulation. For example, β-adrenergic stimulation accelerates recovery from refractoriness at both the cellular and subcellular level ([@bib92]; [@bib77]; [@bib69]). Combined with acceleration of SR Ca--ATPase--mediated SR Ca uptake, accelerated refractoriness serves to support the enhanced Ca cycling required to maintain increased cardiac contractility and beating rate during the adrenergic fight-or-flight response. Notably, the effects of β-adrenergic stimulation on RyR2 refractoriness are dependent on phosphorylation of RyR2-S2808 by PKA as well as Ca/calmodulin-dependent protein kinase II (CaMKII) at RyR2-S2814. Additionally, the effects of β-adrenergic stimulation on RyR2s may involve phosphorylation at -S2030, a site also implicated in enhanced RyR2 sensitivity to cytosolic and/or luminal Ca ([@bib106]; [@bib108]).

In contrast to sympathetic stimulation, parasympathetic stimulation is generally thought to act by slowing cardiac Ca cycling via activation of muscarinic receptors; however, the specific mechanisms of the parasympathetic response and their relation to luminal Ca regulation remain largely unexplored. Recently, we demonstrated ([@bib37]) that, in ventricular myocytes, muscarinic receptor stimulation initiates a distinct mode of EC coupling that operates at reduced intra-SR Ca levels, characteristic of the parasympathetic resting state. In particular, despite less SR Ca content, acetylcholine increased the fraction of Ca released during the cytosolic Ca transient and reduced wasteful diastolic SR Ca leakage. Therefore, in contrast to the performance-oriented mode of EC coupling during sympathetic stimulation, the parasympathetic "efficiency" mode is poised to attain maximal Ca release at minimal SR Ca load, thereby minimizing the energy costs of Ca cycling. The effect of acetylcholine on the fractional release is dependent on phosphorylation of RyR2s at Ser-2808. That, in turn, is accomplished by activation of PKG downstream of the muscarinic receptor type 2. The inhibitory effect of acetylcholine on SR Ca leak was associated with a reduction in RyR2 phosphorylation at Ser-2814, which was mediated by muscarinic receptor type 3, and a reduction in reactive oxygen species--dependent activation of CaMKII. However, further studies are needed to elucidate the mechanisms and physiologic implications of these modulatory influences, in particular, with respect to potential changes in responsiveness to luminal Ca and restitution properties of RyR2.

Molecular basis of control by luminal Ca {#s07}
========================================

Despite the aforementioned evidence for the role of luminal Ca in regulating RyR2 gating, the specific molecular steps of this process are not fully resolved. The RyR2 is complexed with several SR proteins, including CASQ2, TRD, JNT, and HRC, which could facilitate luminal Ca control of RyR2 ([@bib34]; [@bib72]; [@bib29]; [@bib58]). The possibility of direct regulation has also been advanced in studies exploiting heterologous systems overexpressing recombinant RyR2s, as well as those in which the RyR2 was reconstituted in lipid bilayers in the absence of its auxiliary proteins ([@bib42], [@bib43]; [@bib70]). These studies suggested that certain mutations in *RyR2* alter its sensitivity to luminal Ca and diminish intracellular Ca oscillations caused by an increased Ca load. Recently, a point mutation in the *RyR2* (*RyR2*-E4872A) has been proposed to abolish luminal Ca activation of RyR2 without affecting its cytosolic Ca activation ([@bib18]). This mutation is localized in the S6 helix bundle--crossing region, which corresponds to the putative gate structure of RyR2. Moreover, cardiomyocytes isolated from mice, which are heterozygous for this mutation, were reportedly resistant to store overload-induced Ca waves and exhibit reduced arrhythmia burden. Based on these results it has been suggested that direct activation of RyR2 by luminal Ca, independent of accessory proteins or effects of cytosolic Ca causes the release of Ca from the SR ([@bib42], [@bib43]; see Jones et al. in this issue).

Alternatively, studies from several laboratories have suggested that the sensitivity of RyR2 to luminal Ca is mediated by accessory proteins; among which, is CASQ2 ([@bib35], [@bib36]; [@bib6]; [@bib73], [@bib74]). CASQ2 has been shown to facilitate luminal Ca dependence of RyR2s reconstituted in planar lipid bilayers. However, the effects of CASQ2 are dependent on the presence of TRD and JNT ([@bib35]) and are influenced by cytosolic factors, such as ATP ([@bib93]). Additionally, the role of CASQ2 in Ca handling has been demonstrated in experiments using myocytes derived from CASQ KO mice or mice expressing *CASQ2* mutants associated with CPVT ([@bib95]; [@bib103]; [@bib45]). These studies revealed that the absence or functional defects in *CASQ2* result in dysregulated SR Ca release, which, in turn, manifests as an impaired Ca-release termination, shortened Ca-signaling refractoriness, and an enhanced predisposition to aberrant Ca release. However, the effects of CASQ2 as an intra-SR Ca buffer on luminal regulation of RyR2 cannot be completely ruled out. It is noteworthy that the arrhythmogenic effects of at least some of the CPVT-associated *CASQ2* mutants (e.g., R33Q) were independent of changes in Ca buffering. For instance, myocytes that expressed both CASQ2-R33Q and WT CASQ2 exhibited unaltered Ca buffering, as indicated by a lack of change in the SR Ca content ([@bib97]). Hence, these results are consistent with the notion that CASQ2 can regulate RyR2 function independent of its buffering function. Collectively, these results suggest that CASQ2 dynamically regulates RyR2 channels during the cardiac cycle by inhibiting the channel at the lowered luminal Ca concentration after systolic Ca release. Therefore, genetic mutations compromising this inhibitory function of *CASQ2* leave CICR unrestrained, thus facilitating arrhythmogenic aberrant Ca release.

As alluded to above, in addition to regulating RyR2 activity, CASQ2 acts as a major Ca buffer within the SR. In vitro studies have demonstrated that CASQ2 monomers polymerize in a Ca-dependent manner to bind additional Ca and then depolymerize at low luminal Ca levels to release the sequestered Ca ([@bib65], [@bib66]). This raised the intriguing possibility that changes in CASQ2 polymerization, coupled to variations in the SR Ca load, regulate myocyte SR Ca release. The ability of polymerized CASQ2 to change its polymerization state in response to depletion of luminal Ca has been also demonstrated in living cells by measuring fluorescence resonance energy transfer in fibroblasts expressing GFP-- and YFP--CASQ2 fusion proteins ([@bib100]). A recent study by [@bib57] has provided evidence for luminal Ca--dependent changes in polymerization status of CASQ1, the skeletal muscle counterpart of CASQ2, in mouse muscle fibers. Using fluorescence and electron microscopy, these authors demonstrated marked changes in CASQ1 diffusional mobility indicative of depolymerization after SR Ca depletion. These results support the potential role of CASQ in termination of Ca release through either inhibition of RyR2 channels by CASQ monomers or through promoting conformational changes in the Ca release channels thereby promoting channel closure. The slow time course characteristic of such complex protein interactions may account for the delay in restitution of RyR2s from refractoriness after refilling of the SR Ca store. Future studies will have to determine whether similar changes in CASQ2 polymerization occur in cardiac myocytes and whether the time course of those transformations is compatible with beat-to-beat luminal Ca dynamics.

As mentioned, there is evidence implicating other accessory proteins in luminal regulation of RyR2 by Ca, including TRD ([@bib96]; [@bib20]), JNT ([@bib2]), and HRC ([@bib3]). It is, therefore, through the interaction with TRD and JNT ([@bib112]; [@bib34]) that CASQ appears to control the RyR2 function. In support of this intermediary role of the TRD/JNT complex, experiments in lipid bilayer with reconstituted RyR2 revealed that TRD and/or JNT were required for CASQ2-mediated, store-dependent deactivation ([@bib35]). Additionally, overexpression of a decoy peptide corresponding to the CASQ2 binding domain of TRD in cardiomyocytes interfered with the ability of CASQ2 to stabilize SR Ca release ([@bib98]). Although, to date, there is no information as to where TRD binds to the cardiac RyR (RyR2), for its skeletal counterpart (RyR1), the TRD binding region has been shown to reside at residues 4860--4917 (rabbit), near the inner part of the S6 helix bundle-crossing region. Thus, the proposed direct (e.g., [@bib18]) and indirect (i.e., via TRD and CASQ2) effects of luminal Ca seem to converge on the same region, corresponding to the channel gate.

HRC is an intra-SR Ca binding protein that bears similarities to CASQ2. Just like CASQ2, HRC binds to the RyR2 complex through the same CASQ2-binding domain on the TRD ([@bib3]). Insight into the interaction between these two regulatory proteins comes from a study that examined the effects of genetic ablation of HRC alone or both HRC and CASQ2 ([@bib52]). This study revealed that these proteins, rather than being functionally redundant, modulate RyR2 in an opposing manner determined by luminal Ca levels. Specifically, although CASQ2 stabilizes RyR2, rendering it refractory during the diastolic phase, HRC enhances RyR2 activity during that phase, thereby facilitating RyR2 recovery from refractoriness. This, then, raises the possibility of dynamic regulation RyR2 by sequential binding and unbinding of those proteins during various phases of the Ca release--reuptake cycle.

Thus, it appears that regulation of Ca release and refractoriness by the Ca level within the SR involves multiple molecular pathways that include sites on the RyR2 protein itself as well as a system of interacting proteins comprising the RyR2 complex. That system, moreover, appears to interact with regulatory mechanisms residing on the cytosolic side of RyR2, which include Ca-dependent interaction with CaM as well as posttranslational modification of RyR2 (e.g., 2808, 2814, and 2030). Support for that intricate interaction of regulatory mechanisms comes from structural analysis of the RyR2. In particular, recent cryo-electron microscopy studies performed at near-atomic resolution demonstrated that RyR2 is composed of several distinct domains. Those domains constitute a network of superhelical scaffolds for protein binding, as well as offering support for propagation of conformational changes to the RyR2 and facilitating long-range allosteric regulation of the channel activity ([@bib67]). However, additional functional and structural studies are needed to further delineate the cross talk between these regulatory influences in normal and diseased hearts.

Pathological implications of impaired, altered luminal Ca regulation {#s08}
====================================================================

Impaired regulation of SR Ca release is an important factor contributing to various forms of cardiac disease, including cardiac arrhythmias. The role of dysregulated SR Ca release in arrhythmogenesis was first demonstrated in studies examining the mechanisms of arrhythmias associated with digoxin intoxication ([@bib104]). The discovery of CPVTs, cardiac arrhythmias caused by genetic mutations in the RyR2 complex (e.g., *RyR2*, *CASQ2*, *JNT*) established a direct relation between RyR2 dysfunction and arrhythmias ([@bib50]; [@bib51]; [@bib71]; [@bib79]). Parallel studies using various models of ischemic and nonischemic cardiac disease have demonstrated the role of posttranslational modifications in RyR2 in acquired cardiac arrhythmias ([@bib59]; [@bib1]; [@bib113]; [@bib60]; [@bib99]; [@bib21]; [@bib80]; [@bib8], [@bib9], [@bib11]; [@bib78]). In all these pathological settings, it has been shown that arrhythmogenesis involves aberrant diastolic Ca release from the SR, which activates depolarizing currents via the electrogenic NCX, which, in turn, leads to afterdepolarizations and extrasystolic action potentials. Important aspects of Ca-dependent arrhythmogenesis, however, remain to be elucidated. The main areas of uncertainty include the mechanisms of initiation of aberrant Ca release and how impaired regulation by luminal Ca contributes to this arrhythmogenic processes. Furthermore, it is unclear how aberrant Ca-release events are synchronized within a cardiomyocyte and then within the cardiac tissue to elicit triggered activity in the entire myocardium. Growing evidence suggests that these pathologic processes involve shortened Ca-signaling refractoriness from impaired regulation of the RyR2s by luminal Ca.

Generation of aberrant, diastolic SR Ca release {#s09}
===============================================

[@bib28] first demonstrated in mechanically skinned, cardiac myocytes that Ca release from the SR can occur spontaneously, independent of an external Ca trigger, when the Ca content of the SR is elevated. This phenomenon of aberrant Ca release has been investigated in many subsequent studies (reviewed in [@bib41]). It has been demonstrated that the propensity of myocytes toward generation of aberrant Ca release is enhanced by increasing the SR Ca content. These results led to the concept of a SR Ca-content threshold, which postulates that aberrant Ca release occurs when the SR Ca content reaches a certain critical level ([@bib64]; [@bib23]). Moreover, this apparent threshold for aberrant Ca release was reported to be lower in settings of cardiac disease associated with genetic and acquired defects in RyR2s ([@bib42]; [@bib49]; [@bib100]). These results have been interpreted in light of the direct activation of RyR2 by luminal Ca ([@bib70]). However, recent evidence suggests that the notion of an SR Ca content threshold for aberrant Ca release needs to be reexamined.

Specifically, most studies of aberrant Ca release have been either performed in resting, unstimulated cardiac myocytes or in heterologous systems allowing for reconstitution of RyR2s. Those conditions may not be directly applicable to physiologic Ca cycling because that process occurs in the dynamic system of a working heart. Recent experiments with direct, intra-SR monitoring in healthy and postinfarction canine cardiomyocytes demonstrated that aberrant Ca release does not start immediately after luminal Ca reaches its diastolic level ([@bib9]). Instead, a distinct time delay separates the onset of aberrant Ca release from the time of completion of SR refilling, thus arguing against the possibility of threshold-mediated aberrant Ca release. Most of that delay in healthy cardiomyocytes can be attributed to RyR2 refractoriness, which is markedly abbreviated in cardiac disease ([Fig. 1 B](#fig1){ref-type="fig"}). After the complete functional recovery of RyR2s, the onset of aberrant diastolic Ca release is preceded by a brief idle period. Based on theoretical studies ([@bib56]; [@bib62]), that period reflects the time delay required for temporal alignment of stochastic Ca-release sites that exit from refractoriness. That, in turn leads to the generation of global, aberrant Ca release via self-amplifying CICR. An abbreviated refractory period in arrhythmic, postinfarction myocytes permits aberrant Ca release to occur within the diastolic window. A similar abbreviation in RyR2 refractoriness associated with enhanced aberrant Ca release was described in paced myocytes as well as intact hearts from CPVT mice deficient in CASQ2 ([@bib46]; [@bib15]). Thus, rather than being activated directly from within the SR, aberrant Ca release seems to arise because of a CICR-based probabilistic process in which luminal Ca has a regulatory role.

Another important factor in arrhythmogenesis revealed in dynamic studies using physiologically relevant pacing is synchronization of aberrant Ca release. In unstimulated cells, Ca release arises and then propagates as a wave of CICR from one site via a fire-diffuse-fire mechanism. Consequently, Ca wave propagation is relatively slow (20--150 µm/s). On the other hand, in paced myocytes, each action potential-induced systolic-release event presents a synchronizing influence that places all release sites into the same functional state, and hence, temporally aligns their recovery from refractoriness and their stochastic firing. Therefore, shortened refractoriness results in abbreviated latency and exquisitely synchronized firing of Ca-release sites, thus facilitating transition to a form of global release that has characteristics of a Ca phase wave ([@bib41]). Such synchronization of spontaneous release sites in settings of shortened RyR2 refractoriness have been described in both ventricular and atrial myocytes derived from CASQ2-deficient mice phenocopying CPVT ([@bib15]; [@bib53]; [@bib76]).

Synchronization of aberrant, diastolic Ca release in myocardium {#s10}
===============================================================

Although the link between aberrant Ca release and ectopic electrical activity is considered to be well established in isolated myocytes, the mechanism underlying the cross talk between aberrant Ca handling and electrical activity in tissue-wide excitation remains unclear. A fundamental feature of the myocardium, which is lost upon isolation of individual cardiomyocytes, is that within the myocardium, each cell is electrically coupled with neighboring cells. Because of that electrical continuity, the Ca-dependent depolarizing currents generated in any given cell are readily absorbed by the neighboring cells (a phenomenon referred to as source--sink mismatch). Consequently, should a Ca wave arise in any particular cell, its depolarization will be far too small to reach the threshold for generation of an action potential (AP). Computer simulations have suggested that a very large number of cells (\>6 × 10^5^) must synchronously release Ca to generate a sufficient current to overcome that source--sink mismatch and to generate an ectopic beat ([@bib109]). Thus, whether, and in what manner, Ca waves synchronize within the myocardium is a key issue for understanding cardiac arrhythmogenesis. The notion of synchronization of Ca release, as outlined in the previous section for isolated cardiomyocytes, offers a conceptual framework for resolving that issue. Specifically, temporarily aligned Ca release on a cellular level in multiple myocytes across the myocardium may precipitate triggered electrical activity simultaneously in those cells to cause an increase in tissue-wide, premature ventricular beat.

Recently, it was demonstrated that diastolic Ca waves can indeed occur in a highly synchronized manner in multicellular cardiac preparations (trabeculae) in settings of CPVT and are capable of generating triggered APs ([@bib15]). That study, along with others ([@bib105]; [@bib46]; [@bib53]), also identified key factors contributing to synchronization of aberrant Ca release. Similar to isolated myocytes, synchronization of aberrant Ca release in tissue depends on (1) the presence of synchronizing events (systolic APs), which temporally align release-site recovery from refractoriness, and (2) shortened refractoriness that abbreviates the latencies and increases the temporal alignment of spontaneous Ca release events within and between myocytes. Importantly, synchronized, aberrant Ca release can be disrupted by pharmacologic stabilization of RyR2 to prolong Ca-release refractoriness ([@bib15]). Thus, targeting abbreviated Ca-release refractoriness could provide a curative strategy for arrhythmia.

Conclusion and future perspective {#s11}
=================================

In recent years, Ca-signaling refractoriness has emerged as an important concept for understanding myocyte Ca cycling and the rhythmic activity of the heart ([Fig. 2](#fig2){ref-type="fig"}). Importantly, it furnishes a possible explanation for the classic phenomenon of mechanical refractoriness. In essence, it presents a mechanism for dynamic control throughout the cardiac cycle of CICR, a self-perpetuating process with a tendency for "run-away" activation. That process seems to rely mainly on diastolic deactivation of RyR2, driven by a reduction in SR Ca; however, it may be also modulated by the intrinsic and extrinsic factors on the cytosolic side that include Ca activation, Ca-dependent inactivation through CaM, as well as posttranslational modification of the RyR2 itself through phosphorylation and oxidation. As for the molecular mechanisms of luminal regulation, there is evidence for both direct modulation of luminal Ca of the RyR2 and for the role of intermediate luminal Ca sensor molecules, such as CASQ2 or HRC. Moreover, the process appears to be more complex because it may also involve an orchestrated molecular rearrangement of CASQ2 associated with its polymerization and depolymerization based on luminal Ca concentration. Defining the precise molecular and structural basis for regulation by luminal Ca is an important direction for future research. At the same time, Ca signaling refractoriness presents a conceptual framework for understanding dysregulated Ca cycling in cardiac disease. Growing evidence suggests that impairment in RyR2 refractoriness is a unifying mechanism for various forms of inherited and acquired arrhythmias. Specifically, shortened RyR2 refractoriness facilitates synchronous, aberrant, diastolic SR Ca release across the myocardium to induce triggered activity and the resultant malignant arrhythmias. Thus, prolonging RyR2 refractoriness and thereby desynchronizing aberrant Ca release is a logical, next therapeutic step in management of cardiac arrhythmias.

![**Mechanistic and molecular factors determining RyR2 refractoriness and its role in healthy cardiac function and arrhythmogenesis.** RyR2 refractoriness is primarily determined by effects on RyR2 of luminal Ca, i.e., luminal deactivation, and modulated by other factors, including Ca-dependent inhibition of RyR2 by CaM, RyR2 phosphorylation and oxidation, and changes in SR Ca uptake. RyR2 refractoriness is essential for healthy cardiac relaxation and rhythm. Genetic and acquired defects in RyR2 complex result in shortened RyR2 refractoriness, synchronized aberrant Ca cycling, and arrhythmia.](JGP_201711808_Fig2){#fig2}

This work was supported by National Institutes of Health (grants HL074045 and HL063043 to S. Györke) and by the Russian Science Foundation (N15-15-20008 to S. Györke).

The authors declare no competing financial interests.

Eduardo Ríos served as editor.

Abbreviations used:APaction potentialCPVTcatecholaminergic polymorphic ventricular tachycardiaECexcitation--contractionHRChistidine-rich Ca-binding proteinJNTjunctinTRDtriadin
